jRCT2041220047进行中（未招募）不适用
A Phase 3, Placebo-Controlled, Double-Blind Controlled Study of NPC-06 in Patients With Pain Associated with acute Herpes Zoster (NPC-06-6)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Patients aged 18 years or older at the time of informed consent.
- •(2) Patients who are male or female.
- •(3) Patients who are inpatient or outpatient.
- •(4) Patients who are diagnosed with herpes zoster and have acute pain.
- •(5) Patients who are within 28 days after the onset of herpes zoster.
- •(6) Patients whose mean NRS pain score is 4 or higher despite the use of the following drugs during the period between 24 hours and 120 minutes before the study drug administration. During this period, one or two of the following drugs should have been used, and the same drug should have been used at least twice.
- •Non-opioid analgesics (excluding its sustained release formulations and topical drugs used for other sites than the target site for efficacy)
- •Ca2+ channels alpha2delta ligands (excluding gabapentin)
- •Tramadol (excluding its sustained release formulations)
- •An extract from inflammatory rabbit skin inoculated by vaccinia virus
- •(7) Patients whose NRS pain score immediately before the study drug administration is 4 or higher.
- •(8) Patients who are able to perform NRS self-assessment appropriately.
- •(9) Patients who gave written informed consent based on their own free will after receiving adequate explanation and fully understanding the details of the explanation in participating in the study.
排除标准
- •(1) Patients who are suspected to be increased intracranial pressure.
- •(2) Patients who are complicated with epilepsy, serious mental or neuropsychiatric disorders (including dementia, Parkinson's disease, or schizophrenia) or consciousness disturbance.
- •(3) Patients who are being treated for malignancy. However, those who do not interfere with daily life and have good general condition may be included in the study.
- •(4) Patients who are being treated for HIV infection or those who are receiving immunosuppressant (including biologics). However, those who do not interfere with daily life and have good general condition may be included in the study.
- •(5) Patients who are being treated for idiopathic trigeminal neuralgia.
- •(6) Patients who have other severe pain that may affect the assessment of pain associated with acute herpes zoster.
- •(7) Patients who have received non-opioid analgesics (excluding its sustained release formulations and topical drugs used for other sites than the target site for efficacy), Ca2+ channel alpha2delta ligands (excluding gabapentin), tramadol (excluding its sustained release formulations), or an extract from inflammatory rabbit skin inoculated by vaccinia virus during the period from 120 minutes before the study drug administration to the start of study drug administration.
- •(8) Patients who have received the following drugs during the period from 24 hours before the study drug administration to immediately before the study drug administration.
- •Non-opioid analgesics (its sustained release formulations)
- •Gabapentin
- •Tramadol (its sustained release formulations)
- •Opioid analgesics
- •Steroidal anti-inflammatory drugs (systemic) for treatment of herpes zoster and pain associated with acute herpes zoster
- •Antidepressants, antiarrhythmics (excluding those in Vaughan Williams class 2), NMDA receptor antagonists, centrally acting muscle relaxants, and anesthetics (excluding topical drugs used for other sites than the target site for efficacy).
- •(9) Patients who have sinus bradycardia or advanced conduction disturbance.
- •(10) Patients who have a history of hypersensitivity to hydantoin.
- •(11) Patients who are receiving drugs that are contraindicated in the package insert for fosphenytoin.
- •(12) Patients who have received amenamevir during the period from 24 hours before the study drug administration to immediately before the study drug administration.
- •(13) Patients who are complicated with meningitis or have symptoms of meningeal irritation.
- •(14) Patients who have serious cardiac disease, respiratory disorder, or hepatic or renal dysfunction (as a guide, seriousness corresponding to Grade 3 of Standards for Classification of Seriousness of Adverse Drug Reactions [Notification No.80 of the Pharmaceutical Safety Notificatio]).
- •(15) Patients who are receiving fosphenytoin, phenytoin, ethotoin, or a combination of these drugs or have received these drugs as adjuvant analgesics.
- •(16) Patients who have participated in other clinical study within 3 months of the date of the screening test.
- •(17) Pregnant women, lactating women or patients of childbearing potential during the study period.
- •(18) Patients who are unable to give appropriate contraception in accordance with the instructions of the investigator or sub-investigator (hereafter, the investigators) during the period from after obtaining informed consent to the end of the follow-up period.
- •(19) Other patients who are deemed inappropriate for participation in the study by the investigators.
结局指标
主要结局
-
Change in the NRS pain score from baseline at 120 minutes after the study drug administration.
次要结局
- Change in the NRS pain score from baseline at each assessment time point up to 120 minutes after the first maintenance dose(up to 120 minutes after the first maintenance dose)
- Change in the NRS pain score from baseline at each assessment time point after the study drug administration(after the study drug administration)
- Changes in the pain NRS score from the tentative baseline at each assessment time point after the first maintenance dose to immediately before the second maintenance dose(after the first maintenance dose to immediately before the second maintenance dose)
- Time to the first occurrence of the following event (Time to event)(from immediately before the study drug administration to immediately before the second maintenance dose)
- The period of time during which the NRS pain score has been maintained to improve by 2 points or more from baseline
- Proportion of subjects whose NRS pain score has improved by 2 points or more at 120 minutes after the study drug administration from immediately before the study drug administration(120 minutes after the study drug administration)
- Change in the SF-8 (24-hour version) score for QOL from baseline
- Change in the NPSI score (as assessed by type of pain and total score) from baseline
- Number of times non-opioid analgesics used before and after the study drug administration(before and after the study drug administration)
- Proportion of subjects who have continued the maintenance dose
研究者
相似试验
未知
1 期
Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophyDuchenne muscular dystrophyJPRN-jRCT2080223236IPPON SHINYAKU CO., LTD.16
尚未招募
不适用
Clinical evaluation on the pain-reducing effect of Aconinsan for burning mouth syndromeBurning mouth syndromeJPRN-UMIN000044521Saga University64
招募中
1 期
Clinical study of three-step analgesic therapy combined with electroacupuncture in the treatment of moderate and severe cancer pain in advanced pancreatic cancerMalignant tumor of pancreasITMCTR2000003846Yueyang integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
已完成
不适用
ong-term results of pain therapy in patients with CRPS compared to patients with neuralgia and post-traumatic joint pain as a control group - telephone interview 1-5 years after initiation of therapyG56G57M89Mononeuropathies of upper limbMononeuropathies of lower limbOther disorders of boneDRKS00013930Abteilung für Schmerzmedizin Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH Bochum359
已完成
不适用
Comparative evaluation of pain perception during anesthetic injection by Computed controlled automatic anesthesia delivery system and conventional techniquelocal anesthesia.Factors influencing health status and contact with health servicesIRCT2015101024445N2Shiraz University of Medical Sciences50